NASDAQ$MAZE
Maze Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
Maze Therapeutics reported Q2 2025, revenue of $165M.
For Q2 2025, Maze Therapeutics reported revenue of $165M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $165M.
- Maze Therapeutics highlights operating priorities and capital allocation.
- Maze Therapeutics highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Maze Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
The release discusses Maze Therapeutics's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Maze Therapeutics cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q2 2025
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+38.8%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+2.0%
Q2 2025
Best reaction
-2.1%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | +0.4% | -5.6% | |
| Q3 2025 | -2.1% | +6.6% | +37.8% | |
| Q2 2025 | +2.0% | +0.2% | +84.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro